Want to join the conversation?
Biopharmaceutical company $AMGN and Brussels-based UCB announced positive top-line results for romosozumab from pivotal Phase 3 placebo-controlled study evaluating efficacy and safety of romosozumab in treating men with osteoporosis (BRIDGE study). Study met primary endpoint, showing increase in bone mineral density at lumbar spine.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.
It is official, with $T buying $TWX, it looks like distributors want to own the content production too. Expect some good competition between Netflix ($NFLX), AT&T, Comcast ($CMCSA) and others. However, will this be good for the consumers will not be decided soon.
$NFLX a monster move, going up. Expect making some money on Monday.